(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Quarter results today
(bmo 2024-04-28)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States...
Stats | |
---|---|
Dagens volum | 39 191.00 |
Gjennomsnittsvolum | 417 728 |
Markedsverdi | 2.56B |
EPS | €0 ( 2024-03-14 ) |
Neste inntjeningsdato | ( €-0.0100 ) 2024-04-29 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -12.27 |
ATR14 | €0.00700 (0.01%) |
Volum Korrelasjon
MorphoSys AG Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
MorphoSys AG Korrelasjon - Valuta/Råvare
MorphoSys AG Økonomi
Annual | 2023 |
Omsetning: | €238.28M |
Bruttogevinst: | €179.92M (75.51 %) |
EPS: | €-5.53 |
FY | 2023 |
Omsetning: | €238.28M |
Bruttogevinst: | €179.92M (75.51 %) |
EPS: | €-5.53 |
FY | 2022 |
Omsetning: | €278.27M |
Bruttogevinst: | €229.65M (82.53 %) |
EPS: | €-4.42 |
FY | 2021 |
Omsetning: | €179.61M |
Bruttogevinst: | €147.42M (82.08 %) |
EPS: | €-15.40 |
Financial Reports:
No articles found.
MorphoSys AG
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.